IL153831A0 - Methods for therapy of neurodegenerative disease of the brain - Google Patents

Methods for therapy of neurodegenerative disease of the brain

Info

Publication number
IL153831A0
IL153831A0 IL15383101A IL15383101A IL153831A0 IL 153831 A0 IL153831 A0 IL 153831A0 IL 15383101 A IL15383101 A IL 15383101A IL 15383101 A IL15383101 A IL 15383101A IL 153831 A0 IL153831 A0 IL 153831A0
Authority
IL
Israel
Prior art keywords
brain
therapy
methods
neurodegenerative disease
neurodegenerative
Prior art date
Application number
IL15383101A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/620,174 external-priority patent/US6683058B1/en
Application filed by Univ California filed Critical Univ California
Publication of IL153831A0 publication Critical patent/IL153831A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15383101A 2000-07-19 2001-05-17 Methods for therapy of neurodegenerative disease of the brain IL153831A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/620,174 US6683058B1 (en) 1998-04-15 2000-07-19 Methods for therapy of neurodegenerative disease of the brain
PCT/US2001/016122 WO2002007774A2 (en) 2000-07-19 2001-05-17 Methods for therapy of neurodegenerative disease of the brain

Publications (1)

Publication Number Publication Date
IL153831A0 true IL153831A0 (en) 2003-07-31

Family

ID=24484891

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15383101A IL153831A0 (en) 2000-07-19 2001-05-17 Methods for therapy of neurodegenerative disease of the brain
IL153831A IL153831A (en) 2000-07-19 2003-01-07 Pharmaceutical composition for therapy of neurodegenerative disease of the brain

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153831A IL153831A (en) 2000-07-19 2003-01-07 Pharmaceutical composition for therapy of neurodegenerative disease of the brain

Country Status (8)

Country Link
US (3) US20060051322A1 (de)
EP (2) EP1301199B1 (de)
JP (2) JP2004525070A (de)
AU (2) AU6175801A (de)
CA (1) CA2416408A1 (de)
IL (2) IL153831A0 (de)
NZ (1) NZ524070A (de)
WO (1) WO2002007774A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124095A1 (en) 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
EP1773303A2 (de) * 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
US8932208B2 (en) 2005-05-26 2015-01-13 Maquet Cardiovascular Llc Apparatus and methods for performing minimally-invasive surgical procedures
KR20180057737A (ko) * 2005-06-23 2018-05-30 코오롱 티슈진 인크. 신경보호 효과 화합물
ATE460922T1 (de) * 2006-04-07 2010-04-15 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
CA2677273A1 (en) * 2007-02-06 2008-08-14 Tai-June Yoo Use of a composition comprising a cytokine encoding nucleic acid for treating alzheimer's disease
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP2209517A4 (de) 2007-10-05 2011-03-30 Maquet Cardiovascular Llc Vorrichtungen und verfahren für minimal invasive chirurgische eingriffe
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
JP2014527072A (ja) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
WO2014043480A1 (en) 2012-09-13 2014-03-20 Crystal Ronald G Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
GB201308917D0 (en) 2013-05-17 2013-07-03 Renishaw Plc Delivery
US11446084B2 (en) * 2019-07-12 2022-09-20 Neuralink Corp. Laser drilling of pia mater
CN110841059A (zh) * 2019-12-03 2020-02-28 南通大学 老年性痴呆小鼠模型的制备方法
EP4507785A2 (de) * 2022-04-11 2025-02-19 The Broad Institute, Inc. Verstärker für die gerichtete expression von genen in neuronalen zellpopulationen, zusammensetzungen und verfahren dafür

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
JPH03175976A (ja) 1988-12-15 1991-07-31 Takeda Chem Ind Ltd シゾサッカロミセス・ポンベによる動物蛋白質の分泌生産
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
DE69232859T2 (de) * 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
JP3025568B2 (ja) 1992-01-16 2000-03-27 富士通株式会社 光ディスクのデータ再生方法及び装置
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU2677797A (en) * 1996-04-25 1997-11-12 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
AU7154698A (en) * 1997-04-25 1998-11-24 Genentech Inc. Ngf variants
CA2293492A1 (en) * 1997-06-11 1998-12-17 Martin Berry Cns neuroregenerative compositions and methods of use
US6167888B1 (en) * 1997-06-30 2001-01-02 The Regents Of The University Of California Method for inducing partial recovery of lost voluntary motor function after spinal cord injury in a mammal
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
US6812027B2 (en) * 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6815431B2 (en) * 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6683058B1 (en) * 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6054398A (en) 1999-05-14 2000-04-25 Advanced Micro Devices, Inc. Semiconductor interconnect barrier for fluorinated dielectrics

Also Published As

Publication number Publication date
NZ524070A (en) 2008-05-30
AU6175801A (en) 2002-02-05
EP2060267A2 (de) 2009-05-20
WO2002007774A3 (en) 2003-01-16
CA2416408A1 (en) 2002-01-31
JP2013006846A (ja) 2013-01-10
US20090312400A1 (en) 2009-12-17
EP1301199B1 (de) 2017-07-12
AU2001261758B2 (en) 2005-07-21
EP1301199A2 (de) 2003-04-16
EP2060267A3 (de) 2009-08-05
US20060051322A1 (en) 2006-03-09
IL153831A (en) 2013-03-24
US20070249554A1 (en) 2007-10-25
WO2002007774A2 (en) 2002-01-31
US8486385B2 (en) 2013-07-16
JP2004525070A (ja) 2004-08-19

Similar Documents

Publication Publication Date Title
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
AU8119001A (en) Hybrid neuroprosthesis for the treatment of brain disorders
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
PL373626A1 (en) Treatment for central nervous system disorders
AUPQ514600A0 (en) Brain injury treatment
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU6175801A (en) Methods for therapy of neurodegenerative disease of the brain
GB0118383D0 (en) Therapeutic methods
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2000258352A1 (en) Acupuncture points stimulation for treating various diseases
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2266801A (en) Combination therapy for treating neurodegenerative disease
SI1350521T1 (sl) Imunoterapevtske kombinacije za zdravljenje tumorjev
PL373490A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU8339301A (en) Compounds for the treatment of addictive disorders
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
HK1055248A (en) Methods for therapy of neurodegenerative disease of the brain